Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Satish Kumar Ramraj"'
Autor:
Lin Wang, Amy L. Kennedy, Satish Kumar Ramraj, Doris M. Benbrook, Yan D. Zhao, Camille C. Gunderson, Gopal Pathuri, Zitha Redempta Isingizwe, Suganthapriya Elayapillai, Lauri A. Hunsucker, Stanley Lightfoot, Magdalena Bieniasz
Publikováno v:
Gynecol Oncol
Objective Mebendazole and other anti-parasitic drugs are being used off-prescription based on social media and unofficial accounts of their anti-cancer activity. The purpose of this study was to conduct a controlled evaluation of mebendazole's therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbae358207f533e3455beb9b0b218be6
https://pubmed.ncbi.nlm.nih.gov/33131904
https://pubmed.ncbi.nlm.nih.gov/33131904
Autor:
Katie M. Smith, Naveena B. Janakiram, Ankita Raman, Coralee Toal, Doris M. Benbrook, Satish Kumar Ramraj
Publikováno v:
Tissue and Cell. 52:57-64
Human fallopian tube fimbria secretory epithelial cells (hFTSECs) are considered an origin of ovarian cancer and methods for their culture from fallopian tube specimens have been reported. Our objective was to determine whether characteristics of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8dd071f228dcdd9835bd46f5db1d90c
https://doi.org/10.1016/j.tice.2018.04.001
https://doi.org/10.1016/j.tice.2018.04.001
Autor:
Sugantha Priya Elayapillai, Amy L. Kennedy, Zitha Redempta Isingizwe, Richard Pelikan, Stanley Lightfoot, Satish Kumar Ramraj, Doris M. Benbrook, Yan D. Zhao
Publikováno v:
Int J Cancer
Current ovarian cancer maintenance therapy is limited by toxicity and no proven impact on overall survival. To study a maintenance strategy targeted at missense mutant p53, we hypothesized that the release of mutant p53 from mortalin inhibition by th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccb92782ee8ad38e7c160dad3d7ce378
https://pubmed.ncbi.nlm.nih.gov/31845320
https://pubmed.ncbi.nlm.nih.gov/31845320
Autor:
Sheeja Aravindan, Terence S. Herman, Kathiresan Kandasamy, Somasundaram S. Thirugnanasambandan, Natarajan Aravindan, Satish Kumar Ramraj, Dinesh Babu Somasundaram
Publikováno v:
Oncotarget
// Sheeja Aravindan 1,2 , Satishkumar Ramraj 3 , Kathiresan Kandasamy 1 , Somasundaram S. Thirugnanasambandan 1 , Dinesh Babu Somasundaram 3 , Terence S. Herman 2,3 and Natarajan Aravindan 3 1 Department of Marine Sciences, Center of Advanced Study i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f73fba3fe7ccf6c53c481ec3df0db38
http://europepmc.org/articles/PMC5351584
http://europepmc.org/articles/PMC5351584
Autor:
Satish Kumar Ramraj, Sheeja Aravindan, Terence S. Herman, Mohan Natarajan, Dinesh Babu Somasundaram, Natarajan Aravindan
Publikováno v:
Oncotarget
// Satish Kumar Ramraj 1 , Sheeja Aravindan 2 , Dinesh Babu Somasundaram 1 , Terence S. Herman 1, 2 , Mohan Natarajan 3 , Natarajan Aravindan 1 1 Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74d74977285fd4a5db5a2884a445bd09
https://doi.org/10.18632/oncotarget.7615
https://doi.org/10.18632/oncotarget.7615
Autor:
Faizan Haider Khan, Natarajan Aravindan, Vijayabaskar Pandian, Terence S. Herman, Mohan Natarajan, Sheeja Aravindan, Satish Kumar Ramraj, Seifollah Azadi
Publikováno v:
Oncotarget
// Faizan H. Khan 1, * , Vijayabaskar Pandian 1, * , Satish Kumar Ramraj 1, * , Sheeja Aravindan 2 , Mohan Natarajan 3 , Seifollah Azadi 4 , Terence S. Herman 1, 2 , Natarajan Aravindan 1 1 Department of Radiation Oncology, University of Oklahoma Hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa579f66ecf23db3ddf892dd78e6962
https://doi.org/10.18632/oncotarget.5204
https://doi.org/10.18632/oncotarget.5204
Autor:
Doris M. Benbrook, Satish Kumar Ramraj
Publikováno v:
Clinical Cancer Research. 25:NT-104
PURPOSE: TP53 gene missense mutations represent the most common genetic defect in fallopian tube (FT) lesions and high grade serous ovarian cancer (HGSOC) and cause of drug resistance. We hypothesized that drugs with complementary p53 protein-targete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecd664ef6abb3a90827bd230e1501619
https://doi.org/10.1158/1557-3265.ovcasymp18-nt-104
https://doi.org/10.1158/1557-3265.ovcasymp18-nt-104
Autor:
Satish Kumar Ramraj, Zitha Redempta Isingizwe, Sugantha Priya Elayapillai, Amy L. Bosley, Yan Daniel Zhao, Doris M. Benbrook
Publikováno v:
Cancer Research. 79:LB-244
Background: The majority of high-grade serous ovarian cancer patients are diagnosed at late stage and recur after primary chemotherapy and cytoreductive surgery. Our objective was to test low-toxicity drug combinations to prevent ovarian cancer tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b2615eea36ebb10608aea64424424cc
https://doi.org/10.1158/1538-7445.am2019-lb-244
https://doi.org/10.1158/1538-7445.am2019-lb-244
Publikováno v:
Cancer Research. 79:4652-4652
Background High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of ovarian cancer. Standard treatment options have a poor survival rate given high risk of recurrence with chemoresistant disease. Hence, there is a need for novel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50616a132cbe949990a109c51c469c19
https://doi.org/10.1158/1538-7445.am2019-4652
https://doi.org/10.1158/1538-7445.am2019-4652
Autor:
Natarajan Aravindan, Satish Kumar Ramraj, Vijayabaskar Pandian, Faizan Haider Khan, Tasfia Azim
Publikováno v:
Stem Cell Research & Therapy
High-risk neuroblastoma (HR-NB) presenting with hematogenous metastasis is one of the most difficult cancers to cure. Patient survival is poor. Aggressive tumors contain populations of rapidly proliferating clonogens that exhibit stem cell properties
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9437f340158afe3a65e7a301f7aedcb
http://europepmc.org/articles/PMC4759853
http://europepmc.org/articles/PMC4759853